Office Number: 203-815-5782





CaroGen Expands its Board of Directors and Development Leadership Team


Farmington, CT - April 17, 2017:  CaroGen today announced an important addition to its Board of Directors (Dr. Jo Viney) and two key senior executive level scientists (Dr. Steven Mason and Dr. Timur Yarovinsky) to its immunotherapy discovery and development team. Click here to read the full press release


CaroGen and University of Connecticut Colon Cancer Immunotherapy Collaboration Highlighted in Colon Cancer News Today


Farmington, CT - January 26, 2017:  CaroGen and researchers at the University of Connecticut have initiated a collaboration on development of a colon cancer immunotherapy.  This collaboration was highlighted in Colon Cancer News Today.  Click here to read the full article.


UCONN Health Researchers Collaborate with CaroGen Corporation to Develop Vaccine to Treat Colon Cancer


Farmington, CT - November 8, 2016:  The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer.  CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. Click here to read the full press release


CaroGen Forms Zika Vaccine Consortium


Farmington, CT - November 7, 2016:  CaroGen Corporation, announced today that it has formed a consortium comprising CaroGen, the University of Connecticut and Yale University School of Medicine scientists to accelerate the development of a Zika virus vaccine. Click here to read the full press release.


CaroGen Raiess $1M in Series A Funds


Farmington, CT - October 19, 2016:  CaroGen Corporation announced today that it has raised $1 million dollars through GP Fortune Investment Partners (GPFI), LLC, to advance the company's Heptatis B Virus (HBV) immunotherapy.  Click here to read the full press release.


CaroGen in the News:

August 8, 2016:  CaroGen’s CEO Bijan Almassian was profiled by the Hartford Business Journal where he discusses CaroGen's technology, products to treat or prevent Hepatitis B, Zika and C. difficile infections and financing.  Click here to read the full interview.


July 5, 2016: Connecticut Senators Murphy and Blumenthal pushing for Zika virus response funding.  Click here for the story.


SPARK Commercialization Grant Award for C. difficile Vaccine


Farmington, CT - April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection.  The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.



CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B


March 7, 2016:  An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development:  Click here to read the full interview.



CaroGen Announces Publication of HBV Vaccine Preclinical Research


Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.


-Click to Read More-



CaroGen Fostering Vaccine Development  Collaborations with Yale & UConn and Establishing  Laboratory


Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.


-Click to Read More-



CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)


Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.


-Click to Read More-



CaroGen Wins Entrepreneur Innovation Award from CTNext


Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.


-Click to Read More-







The Company’s proprietary virus-like vesicle (VLV) technology is a hybrid of components from two unrelated animal viruses: the alphavirus Semliki Forest virus (SFV) and rhabdovirus vesicular stomatitis virus (VSV), producing particles that have limited replication-competence in vivo. Unlike other viral-based vector vaccines, human infection with SFV and VSV is rare, so the general population is free of pre-existing, virus-neutralizing antibodies that could compromise vaccine efficacy. The VLVs generated can enter into cells of treated subject where, although limited, they propagate sufficiently to express the VLV-encoded antigens to be presented to the host immune system.

Figure 1: Diagram of the hybrid Alphavirus-Rhabdovirus vector for production of VLV. DNA sequence encoding Semliki Forest Virus (SFV) replicase complex (SFVnsp1-4, green) plus Vesicular Stomatitis Virus G-glycoprotein (VSV-G, burgundy) were cloned into the VLV-producing DNA plasmid (circle), separated by SFV SGP (indicated by the large open arrow). Upon introduction (transfection) into mammalian cell lines, such as BHK-21, transcription from the CMV promoter (small open arrow) produces a hybrid vRNA, from which both the SFV replicase and the VSV-G protein are expressed. The latter protein is produced in the endoplasmic reticulum (ER) and transported through the Golgi apparatus to the plasma membrane. Non-specific interactions between the VSV-G cytoplasmic domain and the hybrid vRNA leads to the release of “virus-like vesicles” (VLVs) able to transfer vRNA to new cells. Introduction of coding sequence for various components (proteins, antigens, cytokines, shRNA) downstream of the SGP allows for delivery and expression of these components in VLV-infected cells (Rose et al., PNAS 2014, 111(47):16866-16871).

Advantages of the VLV platform:

  • Delivery of multiple components (antigens, proteins, cytokines, shRNA) from a single VLV – simpler manufacturing and lower cost of goods
  • No pre-existing immunity
  • Capable of robust immune responses to antigens delivered by VLV with no adjuvant required
  • No special delivery devices required
  • Safety – hybrid virus components used are not capable of reverting to a wild-type virus.
  • Safety – no neurotoxicity that may be associated with live viral vectors (van den Pol et al., J. Virology, 2017, 91(6) e02154-16).






CaroGen Corporation


Cell & Genome Sciences Building R2802


400 Farmington Ave


Farmington, CT 06032


Tel: 203-815-5782

Copyright 2013 CaroGen Corporation

About Us